JME Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Molecular Endocrinology (1989) 2, 131-136    DOI: 10.1677/jme.0.0020131
© 1989 Society for Endocrinology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kerr, D. J.
Right arrow Articles by Leake, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerr, D. J.
Right arrow Articles by Leake, R.

The cytostatic effects of {alpha}-interferon may be mediated by transforming growth factor-β

D. J. Kerr, I. B. Pragnell, A. Sproul, S. Cowan, T. Murray, D. George and R. Leake

There is some evidence to suggest that transforming growth factor-β (TGF-β) mediates the cytostatic effects of the anti-oestrogen tamoxifen. In this study we have demonstrated that {alpha}-interferon has a significant anti-proliferative effect on the oestrogen receptor-positive human breast cancer cell line ZR-75. There is decreased phenotypic expression of the oestrogen receptors (to about 30% of control values) and increased TGF-β mRNA. Under the growth conditions used here, ZR-75 cells had approximately 5800 TGF-β binding sites per cell, with an apparent dissociation constant of 70 pM, and we have shown that the anti-proliferative effects of {alpha}-interferon can be reduced by 60% by co-treating the cells with a TGF-β polyclonal antibody. The cytostatic effects of {alpha}-interferon may therefore be mediated by TGF-β in this human breast cancer cell line.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the Society for Endocrinology.